J B Chemicals and Pharmaceuticals (JBCPL) has posted satisfactory performance during the year ended March 2011 and its consolidated net profit increased by 17.3 per cent to Rs.139.32 crore from Rs.118.75 crore in the previous year. The company's consolidated net sales also increased by 17.6 per cent to Rs.871.68 crore from Rs.740.97 crore. The Board of Directors has recommended an equity dividend of 100 per cent (Rs.2 per share of Rs.2 each).


The rest of the world exports (other than Russia and CIS) performed well with 24 per cent growth in sales. This business unit, though has relatively small base, is on good growth trajectory. The domestic formulations business too fared well with 15 per growth in sales, with focus products growing by 17 per cent. The company launched Femident Division that caters to gynecology and dental products. It has increased its medical representative strength to 700 from 544 in the previous year.


The EBDITA increased by 19 per cent to Rs.192.33 crore from Rs.161.66 crore in the previous year. Its employees cost moved up by 18.7 per cent to Rs.124.93 crore. It has successfully reduced its interest burden by 18.7 per cent to Rs.7.37 crore from Rs.9.06 crore . Foreign exchange gains was at Rs.3.18 crore as against Rs.17.07 crore in the previous year.


Its equity capital stood at Rs.16.90 crore and its reserves & surplus increased to Rs.666.83 crore from Rs.547.04 crore, representing a growth of 21.9 per cent.